Aneta Schieferdecker
Dr. med.
Aneta Schieferdecker
  • Assistant physician
Working area

Location

O24 , 4th Floor
Languages
German (Mother tongue)
English

Areas of expertise

Publications

Zurück
  • 2020
  • 2019
  • 2016
  • 2015
  • 2014
Vor

Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma
Schieferdecker A, Hörber S, Ums M, Besemer B, Bokemeyer C, Peter A, Weisel K
BLOOD CANCER J. 2020;10(1):2.

Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund: Woran ist zu denken? Was ist zu tun?
Schieferdecker A, Binder M, Weisel K, Bokemeyer C
DEUT MED WOCHENSCHR. 2019;144(14):982-989.

Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature
Alsdorf W, Schmitz M, Schieferdecker A, Dierlamm J, Bokemeyer C, Binder M
J Oncol Pharm Pract. 2016;22(3):523-7.

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma
Braig F, Voigtländer M, Schieferdecker A, Busch C, Laban S, Grob T, Kriegs M, Knecht R, Bokemeyer C, Binder M
ONCOTARGET. 2016;7(28):42988-42995.

A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma
Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, Pein U, Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M
BLOOD. 2016;127(25):3202-14.

Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins
Schieferdecker A, Shoshani O, Westner B, Zipori D, Fehse B, Kröger N, Ayuketang F
ONCOTARGET. 2016;7(41):67061-67070.

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
Braig F, März M, Schieferdecker A, Schulte A, Voigt M, Stein A, Grob T, Alawi M, Indenbirken D, Kriegs M, Engel E, Vanhoefer U, Grundhoff A, Loges S, Riecken K, Fehse B, Bokemeyer C, Binder M
ONCOTARGET. 2015;6(14):12035-47.

Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia
Rissiek A, Schulze C, Bacher U, Schieferdecker A, Thiele B, Jacholkowski A, Flammiger A, Horn C, Haag F, Tiegs G, Zirlik K, Trepel M, Tolosa E, Binder M
INT J CANCER. 2014;135(10):2370-2379.

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
Schieferdecker A, Voigt M, Riecken K, Braig F, Schinke T, Loges S, Bokemeyer C, Fehse B, Binder M
ONCOTARGET. 2014;5(16):6647-53.

Letzte Aktualisierung aus dem FIS: 01.06.2020 - 06:31 Uhr